Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Palliative Care
  •  Colon Cancer
  •  Radiation Therapy
  •  Hormone Therapy
  •  Stomach Cancer
  •  General Oncology
  •  Neoadjuvant Therapy
  •  Gastrointestinal Cancer

Abstract

Citation: Clin Oncol. 2020;5(1):1704.DOI: 10.25107/2474-1663.1704

Predictors of Apatinib in the Treatment of Advanced Primary Liver Cancer

Ren-Wang Chen, Chi-Dan Wan, Tao Zhang, Liang-Liang Shi, Guo-Run Fan, Jian Chang, Jing Zhan, Xiao-Xiao He, Meng-Jun Qiu, Sheng-Li Yang and Jian-Li Hu

Department of Cancer, Huazhong University of Science and Technology, China Department of Hepatobiliary Surgery, Huazhong University of Science and Technology, China Department of Otorhinolaryngology, Huazhong University of Science and Technology, China Department of Gastroenterology, Huazhong University of Science and Technology, China

*Correspondance to: Jian-Li Hu 

 PDF  Full Text Research Article | Open Access

Abstract:

Objective: The purpose of this study is to investigate the efficacy of Apatinib in the treatment of advanced Primary Liver Cancer (PLC), analyze the factors that influence the efficacy, and find out the biomarkers that effectively predict the efficacy. Methods: Data from 87 patients with advanced PLC who received Apatinib as first-line treatment at two medical centers were retrospectively analyzed. We analyzed the clinical features and explore the prognostic factors of PLC. We correlated the clinical markers with the efficacy of Apatinib. Results: The Progression Free Survival (PFS) of the 87 patients was 8.6 ± 1.9 months (95% CI: 5.0 to 12.3). 3-month, 4-month and 5-month disease control rates were 69.0%, 59.2% and 53.5% respectively. Univariate analysis indicated that Alpha-Feto Protein (AFP), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) and cirrhosis were associated with prognosis (P<0.05). Multivariate analysis indicated that ALP was negatively associated with prognosis (P<0.05). Chisquare test indicated that the serum AFP and LDH level as well as tumor diameter were statistically different between PFS ≤ 3-month and PFS>3-month groups (P<0.05). The survival analysis was conducted that the blood levels of AFP, ALP and LDH as well as with or without cirrhosis before starting Apatinib treatment can influence the survival rate of patients. Conclusion: Apatinib is an effective treatment for advanced PLC. Serum AFP, ALP and LDH level, as well as whether there is cirrhosis can be used to predict the efficacy of Apatinib

Keywords:

Apatinib; Primary liver cancer; First-line treatment; Efficacy prediction; Prognostic factors

Cite the Article:

Chen R-W, Wan C-D, Zhang T, Shi L-L, Fan G-R, Chang J, et al. Predictors of Apatinib in the Treatment of Advanced Primary Liver Cancer. Clin Oncol. 2020; 5: 1704.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Impact of Cytotoxic T Lymphocytes Immunotherapy on Prognosis of Colorectal Cancer Patients
 Abstract  PDF  Full Text
Research on the Role of Ezrin Gene in the Pathological Process of Cervical Cancer
 Abstract  PDF  Full Text
View More...